TapewireFind a company

organization · Reporting owner

Chutzpah Holdings Ltd

Disclosed activity across 1 company

Tapewire entity
50036
SEC CIK
0002055515

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Pluri Inc.PLUR · Entity 772810% ownerMarch 31, 2026May 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pluri Inc.

Report date March 31, 2026 · Filed May 04, 2026

Jointly reported with Manieu Alexandre Weinstein

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectShares indirectly held through Chutzpah Holdings LP937,500 Reported balance After 2026-03-31 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2026-03-31 · Grant · Acquired 312,500 · Balance 937,500

F1: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F4: The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

F5: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Common StockSEC Table I · non-derivativeIndirectShares indirectly held through Chutzpah Holdings LP1,250,000 Reported balance After 2026-04-21 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2026-04-21 · Grant · Acquired 312,500 · Balance 1,250,000

F1: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F5: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Common StockSEC Table I · non-derivativeIndirectShares indirectly held through Chutzpah Holdings LP1,933,415 Reported balance Holding disclosure · report date 2026-03-31 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,933,415

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2027-09-30IndirectWarrants indirectly held through Chutzpah Holdings LP937,500 Reported balance After 2026-03-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-31 · Grant · Acquired 312,500 · Balance 937,500

F1: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F4: The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

F10: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F5: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2027-10-21IndirectWarrants indirectly held through Chutzpah Holdings LP1,250,000 Reported balance After 2026-04-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-04-21 · Grant · Acquired 312,500 · Balance 1,250,000

F1: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F10: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F5: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2026-06-30IndirectWarrants indirectly held through Chutzpah Holdings LP625,000 Reported balance Holding disclosure · report date 2026-03-31 · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · Balance 625,000

F10: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.57 · Expires 2028-02-05IndirectWarrants indirectly held through Chutzpah Holdings LP84,599 Reported balance Holding disclosure · report date 2026-03-31 · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · Balance 84,599

F11: CHL holds warrants to purchase 84,599 Common Shares at an exercise price of $5.568 per share, which were issued pursuant to the Securities Purchase Agreement dated January 23, 2025 between the Company and CHL. These warrants have a term of three years from issuance. The original 19.99% beneficial ownership limitation applicable to these warrants was removed upon receipt of shareholder approval at the Company's 2025 Annual Meeting of Shareholders on June 30, 2025.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Common StockSEC Table I · non-derivativeIndirectPlantae Biosciences Ltd.452,702 Reported balance Holding disclosure · report date 2026-03-31 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 452,702

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Common StockSEC Table I · non-derivativeDirect6,284 Reported balance Holding disclosure · report date 2026-03-31 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 6,284

F8: Represents 5,643 Common Shares received upon vesting of restricted stock units ("RSUs") and 641 RSUs that are scheduled to vest on May 25, 2026 (within 60 days of the date hereof). The 641 RSUs are included in Mr. Weinstein's beneficial ownership pursuant to Rule 13d-3(d)(1) under the Exchange Act because Mr. Weinstein has the right to acquire such shares within 60 days through the settlement of such RSUs. Mr. Weinstein has been granted an aggregate of 10,769 RSUs under two separate equity compensation plan agreements with the Company: (i) 10,250 RSUs granted on February 25, 2025, pursuant to the Company's 2016 Equity Compensation Plan, which vest in twelve installments: 12.50% (1,281 shares) on each of May 25, 2025; August 25, 2025; November 25, 2025; and February 25, 2026; and 6.25% (641 shares, with the final installment being 639 shares)

F9: (Continuation of Footnote (8)) on each of May 25, 2026; August 25, 2026; November 25, 2026; February 25, 2027; May 25, 2027; August 25, 2027; November 25, 2027; and February 25, 2028; and (ii) 519 RSUs granted on December 1, 2025, pursuant to the Company's 2019 Equity Compensation Plan, which vested in three equal monthly installments of 173 shares on December 31, 2025; January 31, 2026; and February 28, 2026 (all of which have now fully vested). As of the date hereof, 5,643 RSUs have vested into Common Shares, and an additional 641 RSUs are scheduled to vest on May 25, 2026 (within 60 days of the date hereof) and are therefore included in Mr. Weinstein's beneficial ownership. The remaining 4,485 RSUs are unvested and subject to future vesting conditions beyond 60 days. Unvested RSUs confer no voting rights or dividend entitlements until settlement into Common Shares.

Filing footnotes · ownership attribution and instrument terms

F1: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F4: The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

F5: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

F8: Represents 5,643 Common Shares received upon vesting of restricted stock units ("RSUs") and 641 RSUs that are scheduled to vest on May 25, 2026 (within 60 days of the date hereof). The 641 RSUs are included in Mr. Weinstein's beneficial ownership pursuant to Rule 13d-3(d)(1) under the Exchange Act because Mr. Weinstein has the right to acquire such shares within 60 days through the settlement of such RSUs. Mr. Weinstein has been granted an aggregate of 10,769 RSUs under two separate equity compensation plan agreements with the Company: (i) 10,250 RSUs granted on February 25, 2025, pursuant to the Company's 2016 Equity Compensation Plan, which vest in twelve installments: 12.50% (1,281 shares) on each of May 25, 2025; August 25, 2025; November 25, 2025; and February 25, 2026; and 6.25% (641 shares, with the final installment being 639 shares)

F9: (Continuation of Footnote (8)) on each of May 25, 2026; August 25, 2026; November 25, 2026; February 25, 2027; May 25, 2027; August 25, 2027; November 25, 2027; and February 25, 2028; and (ii) 519 RSUs granted on December 1, 2025, pursuant to the Company's 2019 Equity Compensation Plan, which vested in three equal monthly installments of 173 shares on December 31, 2025; January 31, 2026; and February 28, 2026 (all of which have now fully vested). As of the date hereof, 5,643 RSUs have vested into Common Shares, and an additional 641 RSUs are scheduled to vest on May 25, 2026 (within 60 days of the date hereof) and are therefore included in Mr. Weinstein's beneficial ownership. The remaining 4,485 RSUs are unvested and subject to future vesting conditions beyond 60 days. Unvested RSUs confer no voting rights or dividend entitlements until settlement into Common Shares.

F10: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F11: CHL holds warrants to purchase 84,599 Common Shares at an exercise price of $5.568 per share, which were issued pursuant to the Securities Purchase Agreement dated January 23, 2025 between the Company and CHL. These warrants have a term of three years from issuance. The original 19.99% beneficial ownership limitation applicable to these warrants was removed upon receipt of shareholder approval at the Company's 2025 Annual Meeting of Shareholders on June 30, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 21, 2026 Filed May 4, 2026 19:37 UTC Pluri Inc. PLUR · Entity 7728 GrantWarrants · Derivative 312,500 $2.00 Strike: $4.25 $625,000.00
Disclosure

SEC source: 0001213900-26-051531 · ownership.xml · derivative · entry 7

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Warrants indirectly held through Chutzpah Holdings LP

Disclosed balance after: 1,250,000

Underlying: Common Shares · 312,500 shares

Expires 2027-10-21

F1 · date: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2 · date: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3 · date: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F10 · derivative.expiration_date: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F5 · balance_after: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7 · ownership.nature: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
April 21, 2026 Filed May 4, 2026 19:37 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Stock 312,500 $2.00 $625,000.00
Disclosure

SEC source: 0001213900-26-051531 · ownership.xml · nonDerivative · entry 2

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings LP

Disclosed balance after: 1,250,000

F1 · date: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2 · date: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3 · date: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F5 · price: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7 · ownership.nature: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
March 31, 2026 Filed May 4, 2026 19:37 UTC Pluri Inc. PLUR · Entity 7728 GrantWarrants · Derivative 312,500 $2.00 Strike: $4.25 $625,000.00
Disclosure

SEC source: 0001213900-26-051531 · ownership.xml · derivative · entry 6

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Warrants indirectly held through Chutzpah Holdings LP

Disclosed balance after: 937,500

Underlying: Common Shares · 312,500 shares

Expires 2027-09-30

F1 · date: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2 · date: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3 · date: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F4 · date: The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

F10 · derivative.expiration_date: The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

F5 · balance_after: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7 · ownership.nature: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
March 31, 2026 Filed May 4, 2026 19:37 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Stock 312,500 $2.00 $625,000.00
Disclosure

SEC source: 0001213900-26-051531 · ownership.xml · nonDerivative · entry 1

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings LP

Disclosed balance after: 937,500

F1 · date: On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

F2 · date: (Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

F3 · date: (Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

F4 · date: The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

F5 · price: The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

F6 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

F7 · ownership.nature: (Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
December 08, 2025 Filed Jan 6, 2026 00:43 UTC Pluri Inc. PLUR · Entity 7728 GrantWarrants · Derivative 625,000 $2.00 Strike: $4.25 $1,250,000.00
Disclosure

SEC source: 0001213900-26-001394 · ownership.xml · derivative · entry 3

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Warrants indirectly held through Chutzpah Holdings LP

Disclosed balance after: 625,000

Underlying: Common Shares · 625,000 shares

Expires 2026-06-30

F1 · balance_after: On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.

F2 · balance_after: (Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.

F3 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
December 08, 2025 Filed Jan 6, 2026 00:43 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Stock 625,000 $2.00 $1,250,000.00
Disclosure

SEC source: 0001213900-26-001394 · ownership.xml · nonDerivative · entry 1

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings LP

Disclosed balance after: 625,000

F1 · balance_after: On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.

F2 · balance_after: (Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.

F3 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

Read SEC document
December 04, 2025 Filed Dec 8, 2025 21:07 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Stock 519 $0.00 $0.00
Disclosure

SEC source: 0001213900-25-119238 · ownership.xml · nonDerivative · entry 1

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,769

F1 · date: The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

F1 · shares: The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

Read SEC document
October 29, 2025 Filed Nov 20, 2025 16:35 UTC Pluri Inc. PLUR · Entity 7728 Exercise / conversionPre-Funded Warrants to purchase Common Shares · Derivative 1,002,169 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001213900-25-112942 · ownership.xml · derivative · entry 4

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 84,599

Underlying: Common Shares · 0 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: In connection with the issuance of common shares in a private placement transaction to Chutzpah on January 23, 2025 (previously reported by the reporting person on Form 3 filed with the Securities and Exchange Commission on February 18, 2025), the reporting person also received 26,030 prefunded warrants to purchase common shares, which, together with the 976,139 prefunded warrants to purchase common shares issued on April 25, 2025 under an amendment to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah, became exercisable following the Company's shareholders meeting on June 30, 2025. The total number of pre-funded warrants being reported after being exercised by the reporting person is 1,002,169 consisting of 976,139 plus 26,030 pre-funded warrants.

F7 · price: Pre-Funded Warrants were acquired in exchange for common shares. Common Warrants were issued as part of the January 23, 2025 transaction for no additional consideration.

F5 · derivative.expiration_date: 1,002,169 pre-funded warrants are being exercised.

F4 · balance_after: On January 23, 2025, Pluri Inc. ("Pluri") entered into a Securities Purchase Agreement with Chutzpah, relating to a private placement offering of: (i) 1,383,948 common shares, par value $0.00001 per share of Pluri, (ii) pre-funded warrants to purchase up to 26,030 Common Shares, and (iii) common warrants to purchase up to 84,599 common shares. The reporting person had previously omitted filing a transaction that occurred on January 1, 2025, which was inadvertently omitted from a prior Form 4. The reporting person became aware of the omission on October 31,2025 and is reporting the transaction promptly after such discovery.

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

Read SEC document
October 29, 2025 Filed Nov 20, 2025 16:35 UTC Pluri Inc. PLUR · Entity 7728 Exercise / conversionCommon Stock 1,002,169 $0.00 $100.22
Disclosure

SEC source: 0001213900-25-112942 · ownership.xml · nonDerivative · entry 2

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 1,933,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · date: In connection with the issuance of common shares in a private placement transaction to Chutzpah on January 23, 2025 (previously reported by the reporting person on Form 3 filed with the Securities and Exchange Commission on February 18, 2025), the reporting person also received 26,030 prefunded warrants to purchase common shares, which, together with the 976,139 prefunded warrants to purchase common shares issued on April 25, 2025 under an amendment to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah, became exercisable following the Company's shareholders meeting on June 30, 2025. The total number of pre-funded warrants being reported after being exercised by the reporting person is 1,002,169 consisting of 976,139 plus 26,030 pre-funded warrants.

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

Read SEC document
April 28, 2025 Filed Jul 1, 2025 20:00 UTC Pluri Inc. PLUR · Entity 7728 OtherPre-Funded Warrants to purchase Common Shares · Derivative 976,139 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001213900-25-060346 · ownership.xml · derivative · entry 5

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 976,139

Underlying: Common Shares · 976,139 shares

Expires not disclosed

F4 · shares: On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

F4 · price: On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

F3 · derivative.exercise_date: The Pre-Funded Warrants are exercisable at any time following the receipt of certain approvals from Pluri Inc.'s (the "Company") shareholders required by the applicable rules of the Nasdaq Capital Market, and remain exercisable until exercised in full.

F3 · derivative.expiration_date: The Pre-Funded Warrants are exercisable at any time following the receipt of certain approvals from Pluri Inc.'s (the "Company") shareholders required by the applicable rules of the Nasdaq Capital Market, and remain exercisable until exercised in full.

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Read SEC document
April 28, 2025 Filed Jul 1, 2025 20:00 UTC Pluri Inc. PLUR · Entity 7728 OtherCommon Stock 976,139 Not disclosed Not disclosed
Disclosure

SEC source: 0001213900-25-060346 · ownership.xml · nonDerivative · entry 4

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 931,246

F4 · shares: On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

F4 · price: On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Read SEC document
April 28, 2025 Filed Jul 1, 2025 20:00 UTC Pluri Inc. PLUR · Entity 7728 PurchaseCommon Stock 452,702 $4.61 $2,086,956.22
Disclosure

SEC source: 0001213900-25-060346 · ownership.xml · nonDerivative · entry 3

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Plantae Bioscience Ltd.

Disclosed balance after: 452,702

F2 · ownership.nature: Mr. Weinstein indirectly owns 77% of Plantae Bioscience Ltd. ("Plantae") and may be deemed to beneficially own securities owned by Plantae. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by Plantae. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Read SEC document
April 28, 2025 Filed Jul 1, 2025 20:00 UTC Pluri Inc. PLUR · Entity 7728 PurchaseCommon Stock 523,437 $4.61 $2,413,044.57
Disclosure

SEC source: 0001213900-25-060346 · ownership.xml · nonDerivative · entry 2

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 931,246

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Read SEC document
April 28, 2025 Filed Nov 20, 2025 16:35 UTC Pluri Inc. PLUR · Entity 7728 PurchaseCommon Stock 452,702 $4.61 $2,086,956.22
Disclosure

SEC source: 0001213900-25-112942 · ownership.xml · nonDerivative · entry 3

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares indirectly held through Plantae Bioscience Ltd.

Disclosed balance after: 452,702

F2 · ownership.nature: Mr. Weinstein indirectly owns 77% of Plantae Bioscience Ltd. ("Plantae") and may be deemed to beneficially own securities owned by Plantae. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by Plantae. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Read SEC document
February 25, 2025 Filed Nov 20, 2025 16:35 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Stock 10,250 $0.00 $0.00
Disclosure

SEC source: 0001213900-25-112942 · ownership.xml · nonDerivative · entry 1

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,250

Read SEC document
January 23, 2025 Filed Nov 20, 2025 16:35 UTC Pluri Inc. PLUR · Entity 7728 GrantCommon Warrants · Derivative 84,599 $0.00 Strike: $5.57 $0.00
Disclosure

SEC source: 0001213900-25-112942 · ownership.xml · derivative · entry 5

Manieu Alexandre Weinstein · CIK 0001833124 · Director · 10% owner

Chutzpah Holdings Ltd · CIK 0002055515 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Indirectly held through Chutzpah Holdings Limited

Disclosed balance after: 84,599

Underlying: Common Shares · 0 shares

Expires not disclosed

F4 · shares: On January 23, 2025, Pluri Inc. ("Pluri") entered into a Securities Purchase Agreement with Chutzpah, relating to a private placement offering of: (i) 1,383,948 common shares, par value $0.00001 per share of Pluri, (ii) pre-funded warrants to purchase up to 26,030 Common Shares, and (iii) common warrants to purchase up to 84,599 common shares. The reporting person had previously omitted filing a transaction that occurred on January 1, 2025, which was inadvertently omitted from a prior Form 4. The reporting person became aware of the omission on October 31,2025 and is reporting the transaction promptly after such discovery.

F7 · price: Pre-Funded Warrants were acquired in exchange for common shares. Common Warrants were issued as part of the January 23, 2025 transaction for no additional consideration.

F6 · derivative.expiration_date: The common warrants are exercisable until June 30, 2028.

F4 · balance_after: On January 23, 2025, Pluri Inc. ("Pluri") entered into a Securities Purchase Agreement with Chutzpah, relating to a private placement offering of: (i) 1,383,948 common shares, par value $0.00001 per share of Pluri, (ii) pre-funded warrants to purchase up to 26,030 Common Shares, and (iii) common warrants to purchase up to 84,599 common shares. The reporting person had previously omitted filing a transaction that occurred on January 1, 2025, which was inadvertently omitted from a prior Form 4. The reporting person became aware of the omission on October 31,2025 and is reporting the transaction promptly after such discovery.

F1 · ownership.nature: This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.